Strikingly, when MM patients were stratified at diagnosis on the basis of the GADD45B mRNA expression in CD138+ cells, the cohort of patients expressing high levels of GADD45B exhibited dramatically shorter progression-free survival and significantly shorter overall survival (OS) than the cohort of patients expressing low levels of GADD45B, despite both groups of patients having been treated with the same velcade/melphalan/prednisone protocol (Palumbo et al., 2010) (Figures 1B and 1C). Here, SDC1 is linked to Miyoshi myopathy.